Newron Pharmaceuticals SpA NWRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NWRN is a good fit for your portfolio.
News
-
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
-
Newron Presents 2023 Financial Results and Provides 2024 Outlook
-
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Trading Information
- Previous Close Price
- €6.69
- Day Range
- €6.71–7.29
- 52-Week Range
- €3.70–10.80
- Bid/Ask
- €0.00 / €7.28
- Market Cap
- €135.64 Mil
- Volume/Avg
- 59,318 / 66,856
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- https://www.newron.com
Comparables
Valuation
|
Metric
|
NWRN
|
PHIL
|
ITM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 324.18 | 36.35 |
Price/Book Value | — | 8.09 | 0.97 |
Price/Sales | 14.75 | 31.50 | 2.46 |
Price/Cash Flow | — | — | 18.32 |
Price/Earnings
NWRN
PHIL
ITM
Financial Strength
|
Metric
|
NWRN
|
PHIL
|
ITM
|
|---|---|---|---|
Quick Ratio | 0.61 | 6.82 | 1.93 |
Current Ratio | 0.68 | 7.02 | 2.34 |
Interest Coverage | −2.93 | −11.02 | 4.26 |
Quick Ratio
NWRN
PHIL
ITM
Profitability
|
Metric
|
NWRN
|
PHIL
|
ITM
|
|---|---|---|---|
Return on Assets (Normalized) | −51.00% | −0.47% | 2.43% |
Return on Equity (Normalized) | — | −0.91% | 3.59% |
Return on Invested Capital (Normalized) | −51.32% | −0.46% | 4.17% |
Return on Assets
NWRN
PHIL
ITM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bzhqnxhc | Mxq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bzlntxtdz | Fchkjq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wpvrsqvf | Knhykh | $97.8 Bil | |
MRNA
| Moderna Inc | Wwdvyhyr | Scdb | $41.3 Bil | |
ARGX
| argenx SE ADR | Pgjdjmsl | Tgyc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kzmxxxkh | Qhgtm | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rqddcwsg | Cpcjdd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tvpprcmy | Rljgbc | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jwzxfsyjq | Cvkmfd | $12.5 Bil | |
INCY
| Incyte Corp | Ccklmhwzx | Ymzcvxr | $11.6 Bil |